RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic … – MarketWatch
|
RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic …
MarketWatch RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi’s lead asset, RYI-008, a novel … San Diego’s RuiYi Raises $15M for Pipeline of Biologic TherapeuticsXconomy RuiYi banks $15M from A-list backers to amp up Chinese R&DFierceBiotech |
